ARH 049020

Drug Profile

ARH 049020

Latest Information Update: 20 Sep 2001

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Peptides
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Insulin resistance; Type 2 diabetes mellitus

Most Recent Events

  • 20 Sep 2001 Discontinued-I for Insulin resistance in United Kingdom (Unknown route)
  • 20 Sep 2001 Discontinued-I for Type-2 diabetes mellitus in United Kingdom (Unknown route)
  • 28 Jun 2001 Phase-I clinical trials for Insulin resistance in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top